Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the complex dermatological effects of oral contraceptives, including both hormonal benefits and potential toxicities, but reports no new clinical results.

Bicalutamide may reduce hair shedding in women but needs longer trials to confirm its effectiveness.

In this study, metformin, pioglitazone, and ethinylestradiol cyproterone all improved various clinical features and quality of life in Pakistani women with PCOS, though no drug significantly reduced hirsutism.

This review found moderate to very low-quality evidence that spironolactone, flutamide, and cyproterone acetate combined with oral contraceptives may reduce hirsutism more effectively than placebo or metformin, though results vary among other treatments.

This retrospective cohort study found that both spironolactone and bicalutamide significantly improved Sinclair grade in women with female pattern hair loss over 24 months, but spironolactone, especially at doses above 100 mg/day, resulted in greater efficacy, required less monitoring, and maintained comparable safety.

This study provides evidence supporting the feasibility of presurgical, window-of-opportunity models to evaluate the preventive potential of candidate agents in cancer, using cases from breast, prostate, and colorectal settings.

This Phase 1 study reported that topical application of BPM31543 was safe and well-tolerated in patients receiving taxane-based chemotherapy, with some experiencing less than 50% hair loss, suggesting potential efficacy in reducing chemotherapy-induced alopecia, although no maximum tolerated dose was identified.

This review found very low certainty in evidence regarding whether statins, alone or in combination with metformin, improve menstrual regularity or other outcomes like hirsutism, acne severity, and testosterone levels, with adverse events showing no significant differences across groups.

This review discusses the role of PPAR-γ in the pathogenesis of primary cicatricial alopecia, including its involvement in lichen planopilaris and treatment trials using PPAR-agonists, and reports no new clinical results.

This case report suggests that the progestogen-only pill may cause false-positive aldosterone/renin ratio results in primary hyperaldosteronism screening, indicating it should be omitted before testing.

Long-term use of oral contraceptives, especially starting before age 20, may increase the risk of early-onset breast cancer.

In a retrospective clinical study, this research found that baricitinib is effective for alopecia areata, with 42.3% of patients achieving a significant reduction in hair loss by week 36, and 52.4% by week 52, outperforming previous trials.

This study observed that patients with severe alopecia areata treated with baricitinib experienced increases in total cholesterol, LDL-C, and HDL-C, consistent with a JAK inhibitor class effect, but the mean increase was modest and lipid-lowering medication initiation was infrequent.

In this open-label study of post-menopausal women with frontal fibrosing alopecia, researchers found that 12 weeks of baricitinib monotherapy significantly reduced disease activity as measured by the Lichen Planopilaris Activity Index, improved patient-reported scalp hair growth, but showed no significant change in eyebrow growth.

This study found that a combination of spironolactone and oral contraceptive pills may improve hirsutism and hormonal profiles in women, although some experienced side effects such as persistent nausea.

This study found that ALRN-6924, a clinical-stage dual inhibitor, can selectively protect human scalp hair follicles from paclitaxel-induced toxicity and damage by inducing transient cell cycle arrest in healthy cells without affecting cancer cells, potentially reducing chemotherapy-induced alopecia.

This paper reviews adverse events related to hedgehog pathway inhibitors in advanced basal cell carcinoma patients, reporting no new clinical results but aiming to inform healthcare professionals for improved patient care.

This study suggests that PF-0998425 is an effective androgen receptor antagonist for sebum control and androgenetic alopecia with rapid metabolism reducing the risk of systemic side effects.

This study found that eribulin-based chemotherapy resulted in longer median progression-free and overall survival, with fewer side effects, for advanced triple-negative breast cancer patients compared to other chemotherapy options.

This study found that curcumin may improve glycemic control and lipid metabolism in patients with PCOS, although its effects on low-density lipoprotein and triglycerides were not significant.

Baricitinib helps regrow hair in teens with severe alopecia areata.

In this study, bicalutamide at low doses was not linked to significant liver enzyme changes compared to other androgen-blocking treatments in transfeminine adolescents and young adults, suggesting its safety with careful monitoring for this population over one year.

This study found that orlistat significantly reduced weight and total testosterone levels in Iranian women with polycystic ovary syndrome after 12 weeks of treatment.

This article discusses the paradoxical effects of valproic acid on hair, reporting both drug-induced hair loss and the potential for hair growth when used topically, but presents no original research findings.

This study investigates the relationship between chemotherapy for cervical cancer, including drugs like Paclitaxel and Cisplatin, and the development of alopecia, highlighting the need for more research to improve symptom management and the crucial role of pharmacists in patient education and care.

This study suggests that adding androgens to menopausal hormone therapy may reduce breast cancer risk by counteracting estrogen-driven proliferation in postmenopausal breast tissue.

This study found that both finasteride and combined oral contraceptives with drospirenone improved reproductive health markers in women with polycystic ovary syndrome without metabolic abnormalities, with each having specific strengths.

This study observed that a combination of low-dose cyclophosphamide and vinorelbine appears safe and has promising antitumor activity in patients with metastatic breast cancer resistant to anthracyclines and taxanes, achieving a 44% objective response rate at 6 months with manageable toxicity levels.